Overall, the SURPASS-AP-Combo trial is consistent with the results reported in previous SURPASS series trials, confirming the efficacy and safety of tsiparatide in the T2D population in the Asia-Pacific region, mainly Chinese patients
On average, though, most categories will see moderate, though undramatic, volume declines
With DACCaveats : Continuous GH exposure may cause receptor downregulation, leading to reduced effectiveness Side effects may occur, such as flushing, water retention, tingling, elevated blood pressure, headaches, and lethargy
As evident, both tirzepatide and retatrutide can induce significant weight loss within the range of 24-25% from baseline after 48-88 weeks of therapy
Your appetite suppression may feel gentle at first, which is normal